Virax Biolabs Group Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Key management compensation

Key management compensation	12 Months Ended
Mar. 31, 2022
Key management compensation [abstract]
Key management compensation	Note 5 — Key management compensation The Company recorded $137,766 and $124,443 consulting fees to the chief executive officer for the years ended March 31, 2022 and 2021, respectively. The Company has a balance of $101,167 and $141,815 owed to the chief executive officer salary as of March 31, 2022 and 2021, respectively. The Company recorded $60,000 and $60,000 consulting fees to the director and chief operating officer for the years ended March 31, 2022 and 2021, respectively. The Company has a balance of $25,016 and $40,994 owed to the chief operating officer salary as of March 31, 2022 and 2021, respectively.

Key management compensation

12 Months Ended

Mar. 31, 2022

Key management compensation [abstract]

Key management compensation

Note 5 — Key management compensation

The Company recorded $137,766 and $124,443 consulting fees to the chief executive officer for the years ended March 31, 2022 and 2021, respectively. The Company has a balance of $101,167 and $141,815 owed to the chief executive officer salary as of March 31, 2022 and 2021, respectively.

The Company recorded $60,000 and $60,000 consulting fees to the director and chief operating officer for the years ended March 31, 2022 and 2021, respectively. The Company has a balance of $25,016 and $40,994 owed to the chief operating officer salary as of March 31, 2022 and 2021, respectively.